AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen

Conclusion of non-exclusive pharmaceutical discount agreement pursuant to § 130a para. 8 SGB V via an open-house model for the active ingredient Tolvaptan (ATC code: C03XA01)

Conclusion of non-exclusive pharmaceutical discount agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Denosumab - Reference: Prolia (ATC code according to WHO: M05BX04)

Conclusion of non-exclusive drug discount agreements pursuant to § 130a Para. 8 SGB V by means of an open-house model for the active ingredient naproxen exclusive of the dosage form syrup (ATC code according to WHO: M01AE02)

Conclusion of non-exclusive drug discount agreement pursuant to § 130a para. 8 SGB V by way of an open-house model for the active ingredient Tolvaptan (ATC code: G04BX21)

Conclusion of non-exclusive drug discount agreements according to § 130a paragraph 8 SGB V by means of an open-house model for the active substance lisdexamfetamine (ATC code according to WHO: N06BA12)

Framework Agreement for the Provision of Temporary Workers under the AÜG

Conclusion of non-exclusive drug discount agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient safinamide (ATC code according to WHO: N04BD03)

Conclusion of non-exclusive pharmaceutical discount agreement pursuant to § 130a paragraph 8 SGB V by means of an open-house model for the active substance Miglustat (ATC code according to WHO: A16AX06)

Germany – Pharmaceuticals – Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient lisdexamfetamine (ATC code according to WHO: N06BA12)

Conclusion of non-exclusive drug discount agreement pursuant to § 130a Para. 8 SGB V by means of an open-house model for the active ingredient Denosumab - Reference: Xgeva (ATC code according to WHO: M05BX04)

Conclusion of non-exclusive drug discount agreement pursuant to § 130a (8) SGB V via an open-house model for the active substance Lisdexamfetamine (ATC code according to WHO: N06BA12)

Document Processor for the Saxony and Thuringia Regions

Framework Agreement for the Provision of (Temporary) Workers in accordance with the AÜG

Conclusion of non-exclusive drug rebate agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active substance Naproxen exclusive of the dosage form syrup (ATC code according to WHO: M01AE02)

Conclusion of non-exclusive pharmaceutical discount agreement pursuant to § 130a para. 8 SGB V via an open-house model for the active substance tolvaptan (ATC code: G04BX21)

Conclusion of non-exclusive drug discount agreement pursuant to § 130a Para. 8 SGB V by means of an open-house model for the active ingredient Denosumab - Reference: Xgeva (ATC code according to WHO: M05BX04)

Conclusion of non-exclusive pharmaceutical discount agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active substance Safinamide (ATC code according to WHO: N04BD03)

Conclusion of non-exclusive drug discount agreements pursuant to § 130a para. 8 SGB V through an open-house model for the active ingredient Denosumab - Reference: Prolia (ATC code according to WHO: M05BX04)

Tender "Dirt trap mats in rental service for AOK PLUS facilities in the Saxony and Thuringia regions"

Region Saxony

Germany – Medicines – Conclusion of non-exclusive pharmaceutical discount agreement pursuant to § 130a para. 8 SGB V via an open-house model for the active ingredient Rivaroxaban (WHO ATC code: B01AF01), restricted to the strengths 10mg/15mg/20mg

Conclusion of non-exclusive AM discount agreement according to § 130a para. 8 SGB V by means of an open-house model for the active ingredient rivaroxaban (ATC code according to WHO: B01AF01), limited to the strengths 10mg/15mg/20mg

Conclusion of non-exclusive drug discount agreements pursuant to § 130a (8) SGB V by means of an open-house model for the active ingredient febuxostat (ATC code according to WHO: M04AA03)

Conclusion of non-exclusive drug discount agreement pursuant to § 130a Abs. 8 SGB V via an open-house model for the active ingredient Tientine (ATC code according to WHO: A16AX12)

Germany – Pharmaceuticals – Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a para. 8 SGB V through an Open House model for the active ingredient epinephrine (ATC code according to WHO: C01CA24) in the dosage form nasal spray

Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient fingolimod (ATC code according to WHO: L04AE01)

Conclusion of non-exclusive drug discount agreements pursuant to § 130a para. 8 SGB V via an open-house model for the active substance Telmisartan (ATC code according to WHO: C09CA07)

Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a Sect. 8 SGB V via an open-house model for the active ingredient Ticagrelor (ATC code according to WHO: B01AC24)

Germany – Pharmaceuticals – Conclusion of non-exclusive pharmaceutical discount agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient dimethyl fumarate (official ATC code: L04AX07)

Conclusion of non-exclusive drug discount agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active substance Omalizumab (ATC code according to WHO: R03DX05)